Vivos Therapeutics(VVOS)

Search documents
Vivos Therapeutics(VVOS) - 2021 Q2 - Quarterly Report
2021-08-12 20:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3224056 (State or other jurisd ...
Vivos Therapeutics(VVOS) - 2021 Q1 - Earnings Call Transcript
2021-05-18 19:18
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2021 Earnings Conference Call May 17, 2021 5:00 PM ET Company Participants Edward Loew - IR Kirk Huntsman - CEO Brad Amman - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Scott Henry - ROTH Capital Operator Good afternoon, and welcome to the Vivos Therapeutics, Inc. Second (sic) [First] Quarter 2021 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Edward ...
Vivos Therapeutics(VVOS) - 2021 Q1 - Quarterly Report
2021-05-17 20:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Delaware 81-3224056 (State or other j ...
Vivos Therapeutics(VVOS) - 2020 Q4 - Annual Report
2021-03-25 20:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) 9137 Ridgeline Boulevard, Suite 135 Highlands Ranch, CO 80129 (Address of principal executive offices) (Zip Code) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39796 Vivos Th ...